Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01514188 · ClinicalTrials.gov registry record · Phase 2
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
A Phase 2 study, sponsored by ImmunityBio.
- Completed
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
NCT01514188 is a Phase 2 study that has completed, run by ImmunityBio. The registered enrollment target is 126 participants.
The verdict
NCT01514188, a Phase 2 study, has completed, sponsored by ImmunityBio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
Study Summary
This is a phase 2b, randomized, open-label, prospective, multicenter study comparing treatment with INNO 206 to doxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who have not been previously treated with any chemotherapy except potentially as adjuvant or neoadjuvant chemotherapy, and no evidence of tumor recurrence has occurred for at least 12 months.
Interventions
- DRUG Doxorubicin
- DRUG INNO-206
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2012-01-11 |
| Est. Completion | 2014-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01514188
The ClinicalTrials.gov registry entry for NCT01514188 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Doxorubicin is the first listed.
NCT01514188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01514188 about?
NCT01514188 is a clinical study titled "Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma". This is a phase 2b, randomized, open-label, prospective, multicenter study comparing treatment with INNO 206 to doxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who have not been previously treated with any chemotherapy except potentially as adjuvant or...
What is the current status of trial NCT01514188?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2012-01-11. Estimated completion is 2014-12-15.
What interventions are being tested in trial NCT01514188?
The interventions under investigation include: Doxorubicin (DRUG), INNO-206 (DRUG).
Who is sponsoring clinical trial NCT01514188?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.